US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

12.36

+0.15001.23%

Volume:520.92K

Turnover:6.38M

Market Cap:461.47M

PE:-5.70

High:12.76

Open:12.23

Low:11.88

Close:12.21

52wk High:16.33

52wk Low:3.35

Shares:37.34M

Float Shares:22.09M

Volume Ratio:1.01

T/O Rate:2.36%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1700

EPS(LYR):-2.1700

ROE:-26.13%

ROA:-17.38%

PB:1.77

PE(LYR):-5.70

Loading ...

Overview Company News Filings

Contineum Therapeutics CEO Carmine N. Stengone Reports Disposal of Common Shares

Chief Scientific Officer Daniel S. Lorrain Reports Sale of Contineum Therapeutics Inc. Common Shares

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares

Contineum Therapeutics CMO Tim Watkins Reports Sale of Common Shares

BRIEF-Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Inducement Plan

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Contineum Therapeutics Launches 2026 Inducement Equity Incentive Plan

Morgan Stanley Downgrades Contineum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $14 From $23

MT Newswires Live

Contineum Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Disposal of Common Shares

Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering

MT Newswires Live

BRIEF-Contineum Therapeutics Prices Upsized $90 Million Public Offering At $12.25 Per Share

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

THOMSON REUTERS

Contineum Therapeutics Inc - Offering of 7.3 Mln Shares at $12.25 per Share

THOMSON REUTERS

BUZZ-Contineum Therapeutics falls on planned $75 million share sale

Contineum Therapeutics Inc - Phase 2 Trial for Pipe-791 Expected to Be Completed in June 2028 - SEC Filing

THOMSON REUTERS

Contineum Therapeutics Is Maintained at Outperform by Baird

Contineum price target lowered to $14 from $16 at Baird

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTNM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CTNM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","market":"US","secType":"STK","nameCN":"Contineum Therapeutics, INC.","latestPrice":12.36,"timestamp":1774292086151,"preClose":12.21,"halted":0,"volume":520918,"delay":0,"changeRate":0.012285012285012168,"floatShares":22092600,"shares":37336000,"eps":-2.169999,"marketStatus":"Trading","change":0.15,"latestTime":"03-23 14:55:07 EDT","open":12.23,"high":12.76,"low":11.88,"amount":6378690.397209999,"amplitude":0.072072,"askPrice":12.43,"askSize":30,"bidPrice":12.3,"bidSize":182,"shortable":3,"etf":0,"ttmEps":-2.169999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":12.21,"postHourTrading":{"tag":"盘后","latestPrice":12.21,"preClose":12.21,"latestTime":"16:21 EDT","volume":180040,"amount":2198247.702,"timestamp":1774038066386,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.008914,"impliedVol":1.0233,"impliedVolPercentile":0.4728},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","floatShares":22092600,"roa":"-17.38%","roe":"-26.13%","lyrEps":-2.169999,"volumeRatio":1.008914,"shares":37336000,"dividePrice":0,"high":12.76,"amplitude":0.072072,"preClose":12.21,"low":11.88,"week52Low":3.35,"pbRate":"1.77","week52High":16.33,"institutionHeld":0,"latestPrice":12.36,"committee":0.716981,"eps":-2.169999,"divideRate":0,"volume":520918,"delay":0,"ttmEps":-2.169999,"open":12.23,"prevYearClose":11.43,"prevWeekClose":12.21,"prevMonthClose":15.34,"prevQuarterClose":11.43,"fiveDayClose":13.37,"twentyDayClose":15.64,"sixtyDayClose":12.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTNM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-05","symbol":"CTNM","fiscalQuarterEnding":"2025/12","expectedEps":-0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-10-30","symbol":"CTNM","fiscalQuarterEnding":"2025/09","expectedEps":-0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1761796800000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2025-08-05","symbol":"CTNM","fiscalQuarterEnding":"2025/06","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2025-05-14","symbol":"CTNM","fiscalQuarterEnding":"2025/03","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.62}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTNM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTNM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.2857,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1767931200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTNM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTNM","date":"2026-03-20","current":-5.695855,"percent":0.324153,"low":-16.425726,"twenty":-10.003778,"median":-5.449385,"eighty":-2.042477,"high":28.322904,"avg":-2.888586,"sd":10.783216,"marketCap":452139395},"quantilePoints":[{"date":"2024-04-05","current":16.281367,"twenty":16.281367,"median":16.281367,"eighty":16.281367,"marketCap":369912656},{"date":"2024-04-12","current":17.609251,"twenty":16.281367,"median":16.569509,"eighty":16.868158,"marketCap":400082176},{"date":"2024-04-19","current":17.122563,"twenty":16.281367,"median":16.868158,"eighty":17.144685,"marketCap":389024629},{"date":"2024-04-26","current":17.686678,"twenty":16.315104,"median":17.089379,"eighty":17.59819,"marketCap":401841332},{"date":"2024-05-03","current":16.48102,"twenty":16.48102,"median":17.122563,"eighty":17.59819,"marketCap":374448771},{"date":"2024-05-10","current":17.719862,"twenty":16.38147,"median":17.105971,"eighty":17.59819,"marketCap":402595255},{"date":"2024-05-17","current":16.547386,"twenty":16.392531,"median":17.100441,"eighty":17.487579,"marketCap":375956618},{"date":"2024-05-24","current":17.819411,"twenty":16.48102,"median":17.133624,"eighty":17.59819,"marketCap":404857026},{"date":"2024-05-31","current":20.173009,"twenty":16.534113,"median":17.172337,"eighty":17.68889,"marketCap":385849140},{"date":"2024-06-07","current":21.67926,"twenty":16.768608,"median":17.354846,"eighty":18.209439,"marketCap":414659209},{"date":"2024-06-14","current":22.311348,"twenty":16.85046,"median":17.388029,"eighty":20.619504,"marketCap":426749148},{"date":"2024-06-21","current":26.466988,"twenty":16.894704,"median":17.487579,"eighty":21.17897,"marketCap":506234071},{"date":"2024-06-28","current":25.216261,"twenty":16.921251,"median":17.542884,"eighty":21.517876,"marketCap":482311425},{"date":"2024-07-05","current":27.018383,"twenty":16.987617,"median":17.609251,"eighty":21.78147,"marketCap":516780614},{"date":"2024-07-12","current":28.242212,"twenty":17.042923,"median":17.692208,"eighty":22.916538,"marketCap":540188796},{"date":"2024-07-15","current":27.932893,"twenty":17.049559,"median":17.697739,"eighty":23.766494,"marketCap":534272442},{"date":"2024-08-02","current":26.224911,"twenty":17.056196,"median":17.697739,"eighty":24.100021,"marketCap":501603882},{"date":"2024-08-09","current":22.338245,"twenty":17.08938,"median":17.819411,"eighty":24.409341,"marketCap":427263614},{"date":"2024-08-16","current":-15.206885,"twenty":17.023013,"median":17.769636,"eighty":24.100021,"marketCap":478195700},{"date":"2024-08-23","current":-14.92058,"twenty":16.547386,"median":17.697739,"eighty":23.683112,"marketCap":469192554},{"date":"2024-08-30","current":-15.468649,"twenty":16.315104,"median":17.614781,"eighty":23.293101,"marketCap":486427149},{"date":"2024-09-06","current":-14.511573,"twenty":15.417858,"median":17.570537,"eighty":22.830467,"marketCap":456330916},{"date":"2024-09-13","current":-14.765157,"twenty":-14.025672,"median":17.410151,"eighty":22.682531,"marketCap":464305131},{"date":"2024-09-20","current":-16.425726,"twenty":-14.408503,"median":17.365907,"eighty":22.459283,"marketCap":516523382},{"date":"2024-09-27","current":-15.272326,"twenty":-14.745525,"median":17.19999,"eighty":22.405488,"marketCap":480253562},{"date":"2024-10-04","current":-14.421591,"twenty":-14.887859,"median":17.133624,"eighty":22.351694,"marketCap":453501355},{"date":"2024-10-11","current":-13.521775,"twenty":-14.788061,"median":17.100441,"eighty":22.316727,"marketCap":425205752},{"date":"2024-10-18","current":-13.480875,"twenty":-14.745525,"median":17.039604,"eighty":22.010098,"marketCap":423919588},{"date":"2024-10-25","current":-13.309092,"twenty":-14.662087,"median":16.868158,"eighty":21.934785,"marketCap":418517700},{"date":"2024-10-31","current":-14.004404,"twenty":-14.595828,"median":16.547386,"eighty":21.78147,"marketCap":440382485},{"date":"2024-11-08","current":-13.455721,"twenty":-14.532841,"median":16.387,"eighty":21.655052,"marketCap":477166769},{"date":"2024-11-15","current":-13.193473,"twenty":-14.477216,"median":16.281367,"eighty":21.566291,"marketCap":467866942},{"date":"2024-11-22","current":-10.423934,"twenty":-14.434679,"median":15.167037,"eighty":21.517876,"marketCap":369653551},{"date":"2024-11-29","current":-10.838275,"twenty":-14.411775,"median":-9.795154,"eighty":21.388769,"marketCap":384346893},{"date":"2024-12-06","current":-10.358512,"twenty":-14.347406,"median":-10.271282,"eighty":21.17897,"marketCap":367333550},{"date":"2024-12-13","current":-10.031401,"twenty":-14.270231,"median":-10.358512,"eighty":21.154762,"marketCap":355733543},{"date":"2024-12-20","current":-9.70429,"twenty":-14.217087,"median":-10.242206,"eighty":20.950342,"marketCap":344133536},{"date":"2024-12-27","current":-10.569317,"twenty":-14.14183,"median":-10.271282,"eighty":20.635643,"marketCap":374809110},{"date":"2025-01-03","current":-10.525702,"twenty":-14.135286,"median":-10.358512,"eighty":20.603366,"marketCap":373262442},{"date":"2025-01-10","current":-9.718828,"twenty":-14.073857,"median":-10.358512,"eighty":20.25908,"marketCap":344649092},{"date":"2025-01-17","current":-9.071876,"twenty":-14.047944,"median":-10.256744,"eighty":19.850241,"marketCap":321706856},{"date":"2025-01-24","current":-8.19958,"twenty":-14.045305,"median":-10.209494,"eighty":18.599466,"marketCap":290773505},{"date":"2025-01-31","current":-7.429052,"twenty":-14.035488,"median":-10.009594,"eighty":17.759682,"marketCap":263449044},{"date":"2025-02-07","current":-6.883867,"twenty":-14.024036,"median":-9.925999,"eighty":17.706588,"marketCap":244115699},{"date":"2025-02-14","current":-5.589962,"twenty":-14.010948,"median":-9.718828,"eighty":17.697739,"marketCap":198231228},{"date":"2025-02-21","current":-5.742614,"twenty":-13.988044,"median":-9.667944,"eighty":17.693315,"marketCap":203644564},{"date":"2025-02-28","current":-5.19016,"twenty":-13.940599,"median":-9.518928,"eighty":17.660132,"marketCap":184053442},{"date":"2025-03-07","current":-3.942751,"twenty":-13.847345,"median":-9.071876,"eighty":17.615888,"marketCap":166612775},{"date":"2025-03-14","current":-4.371311,"twenty":-13.716463,"median":-8.19958,"eighty":17.604827,"marketCap":184722859},{"date":"2025-03-21","current":-4.377433,"twenty":-13.63957,"median":-8.126889,"eighty":17.576068,"marketCap":184981575},{"date":"2025-03-28","current":-4.561102,"twenty":-13.619937,"median":-7.567165,"eighty":17.520762,"marketCap":192743040},{"date":"2025-04-04","current":-3.75296,"twenty":-13.617995,"median":-7.116479,"eighty":17.456608,"marketCap":158592595},{"date":"2025-04-11","current":-2.528503,"twenty":-13.600664,"median":-6.847522,"eighty":17.401302,"marketCap":106849497},{"date":"2025-04-17","current":-2.681561,"twenty":-13.574128,"median":-6.436815,"eighty":17.385817,"marketCap":113317384},{"date":"2025-04-25","current":-2.767272,"twenty":-13.55286,"median":-5.742614,"eighty":17.372544,"marketCap":116939401},{"date":"2025-05-02","current":-2.430547,"twenty":-13.541408,"median":-5.640845,"eighty":17.334936,"marketCap":102710049},{"date":"2025-05-09","current":-2.418302,"twenty":-13.513595,"median":-5.553616,"eighty":17.244235,"marketCap":102192618},{"date":"2025-05-16","current":-2.045592,"twenty":-13.477603,"median":-5.430041,"eighty":17.188929,"marketCap":101933903},{"date":"2025-05-23","current":-2.030017,"twenty":-13.462755,"median":-5.321004,"eighty":17.144685,"marketCap":101157756},{"date":"2025-05-30","current":-1.853493,"twenty":-13.455721,"median":-5.117468,"eighty":17.144685,"marketCap":92361429},{"date":"2025-06-06","current":-2.154621,"twenty":-13.448154,"median":-4.770625,"eighty":17.122563,"marketCap":107366928},{"date":"2025-06-13","current":-2.40383,"twenty":-13.399073,"median":-4.628447,"eighty":17.122563,"marketCap":119785271},{"date":"2025-06-20","current":-1.895028,"twenty":-13.379975,"median":-4.585591,"eighty":17.104865,"marketCap":94431153},{"date":"2025-06-27","current":-2.081935,"twenty":-13.328858,"median":-4.536848,"eighty":17.091592,"marketCap":103744911},{"date":"2025-07-03","current":-2.014441,"twenty":-13.312364,"median":-4.445597,"eighty":17.06947,"marketCap":100381610},{"date":"2025-07-11","current":-2.092319,"twenty":-13.309092,"median":-4.377433,"eighty":17.036286,"marketCap":104262342},{"date":"2025-07-18","current":-1.993674,"twenty":-13.304184,"median":-4.325394,"eighty":16.96992,"marketCap":99346748},{"date":"2025-07-25","current":-2.959359,"twenty":-13.281279,"median":-4.150909,"eighty":16.894704,"marketCap":147467829},{"date":"2025-08-01","current":-3.063196,"twenty":-13.22336,"median":-4.01928,"eighty":16.841612,"marketCap":152642139},{"date":"2025-08-08","current":-3.062072,"twenty":-13.164683,"median":-3.75296,"eighty":16.657997,"marketCap":174115524},{"date":"2025-08-15","current":-3.58032,"twenty":-12.764301,"median":-3.489183,"eighty":16.507566,"marketCap":203584157},{"date":"2025-08-22","current":-4.951297,"twenty":-12.507357,"median":-3.639499,"eighty":16.427927,"marketCap":281540625},{"date":"2025-08-29","current":-4.956228,"twenty":-11.906412,"median":-3.948873,"eighty":16.385894,"marketCap":281821044},{"date":"2025-09-05","current":-5.419796,"twenty":-11.370375,"median":-4.039068,"eighty":16.354924,"marketCap":308180426},{"date":"2025-09-12","current":-5.824184,"twenty":-11.101417,"median":-4.150909,"eighty":16.301609,"marketCap":331174779},{"date":"2025-09-19","current":-6.115147,"twenty":-10.938589,"median":-4.325394,"eighty":16.232919,"marketCap":347719498},{"date":"2025-09-26","current":-5.355685,"twenty":-10.838275,"median":-4.374303,"eighty":15.930178,"marketCap":304534979},{"date":"2025-10-03","current":-5.301438,"twenty":-10.774307,"median":-4.411924,"eighty":15.250644,"marketCap":301450371},{"date":"2025-10-10","current":-5.996789,"twenty":-10.666723,"median":-4.53049,"eighty":8.143309,"marketCap":340989443},{"date":"2025-10-17","current":-6.144737,"twenty":-10.617293,"median":-4.573346,"eighty":-1.787038,"marketCap":349402011},{"date":"2025-10-24","current":-5.483906,"twenty":-10.566409,"median":-4.58636,"eighty":-1.820784,"marketCap":311825872},{"date":"2025-10-31","current":-5.197875,"twenty":-10.55914,"median":-4.692731,"eighty":-1.833764,"marketCap":295561573},{"date":"2025-11-07","current":-5.410266,"twenty":-10.548963,"median":-4.832939,"eighty":-1.851935,"marketCap":321299446},{"date":"2025-11-14","current":-5.356212,"twenty":-10.534425,"median":-4.919242,"eighty":-1.870107,"marketCap":318089369},{"date":"2025-11-21","current":-6.004854,"twenty":-10.522794,"median":-4.956228,"eighty":-1.897105,"marketCap":356610284},{"date":"2025-11-28","current":-5.439749,"twenty":-10.511164,"median":-5.1056,"eighty":-1.907489,"marketCap":323050396},{"date":"2025-12-05","current":-5.395524,"twenty":-10.480633,"median":-5.127036,"eighty":-1.940717,"marketCap":320423970},{"date":"2025-12-12","current":-6.422541,"twenty":-10.474818,"median":-5.15474,"eighty":-1.961484,"marketCap":381415418},{"date":"2025-12-19","current":-5.596996,"twenty":-10.473364,"median":-5.194017,"eighty":-1.980175,"marketCap":332388800},{"date":"2025-12-26","current":-6.230896,"twenty":-10.467549,"median":-5.225482,"eighty":-1.988482,"marketCap":370034239},{"date":"2026-01-02","current":-5.616652,"twenty":-10.432657,"median":-5.250562,"eighty":-1.988482,"marketCap":333556100},{"date":"2026-01-09","current":-5.640545,"twenty":-10.418119,"median":-5.238277,"eighty":-1.992636,"marketCap":334975047},{"date":"2026-01-16","current":-7.282885,"twenty":-10.370143,"median":-5.311221,"eighty":-1.993674,"marketCap":432508676},{"date":"2026-01-23","current":-7.76882,"twenty":-10.358512,"median":-5.340862,"eighty":-1.996789,"marketCap":461366940},{"date":"2026-01-30","current":-8.980584,"twenty":-10.345428,"median":-5.356212,"eighty":-2.000423,"marketCap":533329955},{"date":"2026-02-06","current":-8.906771,"twenty":-10.297451,"median":-5.376869,"eighty":-2.009249,"marketCap":528946421},{"date":"2026-02-13","current":-9.152815,"twenty":-10.253836,"median":-5.386426,"eighty":-2.014441,"marketCap":543558201},{"date":"2026-02-20","current":-9.841736,"twenty":-10.233483,"median":-5.400438,"eighty":-2.020671,"marketCap":584471184},{"date":"2026-02-27","current":-9.706412,"twenty":-10.211675,"median":-5.415031,"eighty":-2.032093,"marketCap":576434705},{"date":"2026-03-06","current":-8.494648,"twenty":-10.131715,"median":-5.429659,"eighty":-2.035208,"marketCap":504471690},{"date":"2026-03-13","current":-8.627788,"twenty":-10.022678,"median":-5.439635,"eighty":-2.037285,"marketCap":517477458},{"date":"2026-03-20","current":-7.538421,"twenty":-10.003778,"median":-5.449385,"eighty":-2.042477,"marketCap":452139395}],"updateTime":1774292107577},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTNM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611939641","title":"Contineum Therapeutics CEO Carmine N. Stengone Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611939641","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611939641?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:28","pubTimestamp":1771018109,"startTime":"0","endTime":"0","summary":"Carmine N. Stengone, CEO and President of Contineum Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL5zlq4l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2611193982","title":"Chief Scientific Officer Daniel S. Lorrain Reports Sale of Contineum Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193982","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193982?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:26","pubTimestamp":1771018009,"startTime":"0","endTime":"0","summary":"Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL12rzYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Scientific Officer Daniel S. Lorrain Reports Sale of Contineum Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2609582907","title":"Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609582907","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609582907?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:25","pubTimestamp":1770326733,"startTime":"0","endTime":"0","summary":"Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL1lDmj1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2607902495","title":"Contineum Therapeutics CMO Tim Watkins Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2607902495","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607902495?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:52","pubTimestamp":1769809954,"startTime":"0","endTime":"0","summary":"Tim Watkins, Chief Medical Officer & Head of Development at Contineum Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL9Ylq4s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Contineum Therapeutics CMO Tim Watkins Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2607272877","title":"BRIEF-Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2607272877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607272877?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:28","pubTimestamp":1769635731,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule Jan 28 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTIN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA651RSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2607740663","title":"Contineum Therapeutics Grants Stock Options to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2607740663","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607740663?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:05","pubTimestamp":1769634323,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Inc. has granted a non-qualified stock option to purchase 23,000 shares of Class A common stock to a new non-executive employee. The stock option vests over four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining shares vesting monthly over the following 36 months. The option has an exercise price equal to the closing price of the company’s Class A common stock on the grant date and a ten-year term. This grant was made under the company's 2026 Employment Inducement Equity Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on January 28, 2026","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL26y1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2607174055","title":"Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607174055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607174055?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:05","pubTimestamp":1769634300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA651RSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2606265622","title":"Contineum Therapeutics Launches 2026 Inducement Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2606265622","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606265622?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:07","pubTimestamp":1769461642,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Inc. has approved the 2026 Employment Inducement Equity Incentive Plan, which reserves 750,000 shares of Class A common stock for issuance as equity awards. The plan allows for the granting of stock options and restricted stock units to new employees as an incentive for joining the company. The plan’s terms are largely similar to the company’s 2024 Equity Incentive Plan, with the exception that incentive stock options are not included. Full details of the plan and related agreements will be included in the company’s upcoming annual report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDLbmlRjh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2601361626","title":"Morgan Stanley Downgrades Contineum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $14 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2601361626","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601361626?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:43","pubTimestamp":1767876221,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics (CTNM) has an average rating of buy and mean price target of $20.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTNM"],"gpt_icon":0},{"id":"2601780369","title":"Contineum Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2601780369","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601780369?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:29","pubTimestamp":1767875340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 07:29 ET (12:29 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM"],"gpt_icon":0},{"id":"2601433408","title":"Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601433408","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601433408?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:17","pubTimestamp":1767734227,"startTime":"0","endTime":"0","summary":"Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDLb0tGXg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2595717409","title":"Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595717409","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595717409?lang=en_us&edition=fundamental","pubTime":"2025-12-31 05:11","pubTimestamp":1767129069,"startTime":"0","endTime":"0","summary":"Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL3yCz7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2590579156","title":"Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590579156","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590579156?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:19","pubTimestamp":1765527570,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  said late Thursday it priced its upsized underwritten public offering of about 7.3 million of class A shares at $12.25 apiece for gross proceeds of around $90 million.The company has granted underwriters a 30-day option to purchase up to an additional 1.1 million class A shares at the offering price.The offering is expected to close on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2590219565","title":"BRIEF-Contineum Therapeutics Prices Upsized $90 Million Public Offering At $12.25 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590219565","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590219565?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:26","pubTimestamp":1765509967,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Prices Upsized $90 Million Public Offering At $12.25 Per ShareDec 11 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $90.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6TSXD6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2590616521","title":"Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590616521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590616521?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:24","pubTimestamp":1765509842,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6TSXD6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2590521615","title":"Contineum Therapeutics Inc - Offering of 7.3 Mln Shares at $12.25 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590521615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590521615?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:24","pubTimestamp":1765509842,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6TSXD6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2590544343","title":"BUZZ-Contineum Therapeutics falls on planned $75 million share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2590544343","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590544343?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:59","pubTimestamp":1765490360,"startTime":"0","endTime":"0","summary":"BUZZ-Contineum Therapeutics falls on planned $75 million share sale** Drug developer Contineum Therapeutics' CTNM.O shares fall 2.5% to $12.74 in extended trading** CTNM kicks off public offering of $75 million worth of shares** Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets and William Blair are joint book-running managers for proposed offering** Proceeds will be used to advance the development of its experimental drug, PIPE-791, and to fund research and development activities, among other purposes** CTNM has 29.2 million outstanding shares for $365.4 million market cap, per LSEG data** All seven brokerages covering the stock rate it \"buy\" or higher; median PT $22 — data compiled by LSEG** As of last close, CTNM down 10.8% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL6N3XH172:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2750360641.GBP","LU2237443978.SGD","IE00B19Z3581.USD","LU2237443895.HKD","LU2471134796.USD","IE0004091025.USD","LU1868837136.USD","CTNM","LU0251131958.USD","LU1868836914.USD","LU0061475181.USD","LU1868836757.USD","BK4588","LU0251142724.SGD","LU2750360997.AUD","LU0345770308.USD","LU2237443549.SGD","LU2237443622.USD","BK4550","IE00BFXG1179.USD","IE0034235188.USD","LU0345770993.USD","LU1668664300.SGD","LU2237443382.USD","LU1868836591.USD","IE0004086264.USD","BK4207","SF","BK4533","IE00BSNM7G36.USD","LU1868837300.USD","BK4504","LU1894683264.USD","LU2471134879.HKD","BK4516","LU1804176565.USD","LU2471134952.CNY","LU1894683348.USD","LU0106831901.USD","LU1791807156.HKD","LU2237443465.HKD","MNSH","LU0096364046.USD","LU2237438978.USD","BK4552","BK4007","IE0002270589.USD","BK4585","BK4127","LU0048573561.USD"],"gpt_icon":0},{"id":"2590954172","title":"Contineum Therapeutics Inc - Phase 2 Trial for Pipe-791 Expected to Be Completed in June 2028 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590954172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590954172?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:45","pubTimestamp":1765489517,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585383493","title":"Contineum Therapeutics Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2585383493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585383493?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:54","pubTimestamp":1763996040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 09:54 ET (14:54 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM"],"gpt_icon":0},{"id":"2585464603","title":"Contineum price target lowered to $14 from $16 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2585464603","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585464603?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:35","pubTimestamp":1763987720,"startTime":"0","endTime":"0","summary":"Baird lowered the firm’s price target on Contineum (CTNM) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated its model ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-price-target-lowered-to-14-from-16-at-baird-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-price-target-lowered-to-14-from-16-at-baird-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":76,"code":"91000000","status":"200"}]}}